Assay development and screening for discovery of chemical probes, drugs or immunomodulators (R01 Clinical Trial Not Allowed)

National Institutes of HealthAmount not specifiedDue in 17 days

Researchers Schools & universities Broad eligibility Deadline soon

Deadline: Sep 7, 2026
Posted: Nov 6, 2024
Award amount: Amount not specified
Focus areas: Education Health

Don’t miss this deadline

We’ll email you before Sep 7, 2026 so you have time to apply.

In plain English

This NIH/National Cancer Institute R01 award supports assay development and screening to discover small-molecule chemical probes, drugs, or immunomodulators, with no clinical trials allowed. It is aimed at research institutions and investigators conducting early-stage discovery research, and lists a broad set of eligible U.S. organization types. Funding amounts are not specified here. Applications are submitted through eligible organizations.

AI-generated summary to help you decide quickly — verify the official eligibility rules before applying.

Who can apply

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

About this grant

Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications for identification of small molecules that function to elucidate the biology of disease as chemical probes or function as agonists or antagonists of disease target(s) for therapy or immunotherapy. The NOFO is intended to support discovery research for the identification of validated hits relevant to health-related outcomes of participating NIH Institutes. Stages of discovery research covered by this NOFO include: 1) assay development for specific biological targets and disease mechanisms relevant to the mission of participating NIH Institutes with the intent to screen for small molecule compounds that show potential as probes for use in advancing knowledge about the known targets, identifying new targets, or as pre-therapeutic leads; 2) screen implementation high throughput target-focused approaches or moderate throughput phenotypic- and fragment-based approaches to identify initial screening hits; 3) hit validation, including implementation of secondary assays that are orthogonal to the primary assay, advanced cheminformatics analysis and initial medicinal chemistry inspection to prioritize the hit set, and follow-up assays to characterize mode and mechanism of action of the validated hits; 4) hit-to-lead optimization, including SAR to optimize target engagement, selectivity and to minimize chemical liabilities, ADME, PK and PD studies, and, if appropriate, in vivo modeling to test efficacy or biological effects.

Let AI draft your application

Your first draft is free: a narrative and budget outline tailored to this grant, emailed to you. Drafts are written in a nightly batch, so it arrives by email later — not instantly on this page.

Application Kit — $49 one-time

Winner intelligence + a first-draft narrative grounded in applications that actually won. One payment, no subscription.

Get the Application Kit →

Related grants

Other open grants funding Education and Health — soonest deadline first.

Also listed under National Institutes of Health, Education Grants and Health Grants.

Source: public records via Grants.gov. UseGrants is an independent aggregator, not affiliated with any funding agency. Always confirm details on the official listing before applying.